Literature DB >> 3768242

Pharmacodynamics and pharmacokinetics of single doses of ketanserin and propranolol alone and in combination in healthy volunteers.

F M Williams, J E Leeser, M D Rawlins.   

Abstract

The potential interaction between ketanserin and propranolol has been investigated in eight healthy volunteers. Volunteers received single doses of placebo, propranolol (80 mg), ketanserin (20 mg), and propranolol (80 mg) plus ketanserin (20 mg) following a randomised double-blind regimen. A single dose of ketanserin had little effect on resting heart rate and blood pressure and the effects of propranolol and ketanserin in combination were similar to those of propranolol alone. The inhibition of exercise induced tachycardia by propranolol was not affected by ketanserin. The pharmacokinetics of propranolol elimination were not influenced by the concurrent administration of ketanserin, nor the pharmacokinetics of ketanserin by propranolol.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3768242      PMCID: PMC1401118          DOI: 10.1111/j.1365-2125.1986.tb02891.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  9 in total

1.  Antihypertensive properties of ketanserin in combination with beta-adrenergic blocking agents.

Authors:  T Hedner; B Persson
Journal:  J Cardiovasc Pharmacol       Date:  1985       Impact factor: 3.105

2.  Mechanism of antihypertensive action of ketanserin in man.

Authors:  I W Reimann; J C Frölich
Journal:  Br Med J (Clin Res Ed)       Date:  1983-08-06

3.  Responses of the systemic circulation and of the renin-angiotensin-aldosterone system to ketanserin at rest and exercise in normal man.

Authors:  R Fagard; A Cattaert; P Lijnen; J Staessen; L Vanhees; E Moerman; A Amery
Journal:  Clin Sci (Lond)       Date:  1984-01       Impact factor: 6.124

4.  An automated HPLC method for the assay of propranolol and its basic metabolites in plasma and urine.

Authors:  M W Lo; B Silber; S Riegelman
Journal:  J Chromatogr Sci       Date:  1982-03       Impact factor: 1.618

5.  Immediate cardiovascular responses to oral prazosin--effects of concurrent beta-blockers.

Authors:  H L Elliott; K McLean; D J Sumner; P A Meredith; J L Reid
Journal:  Clin Pharmacol Ther       Date:  1981-03       Impact factor: 6.875

6.  Ketanserin, a novel 5-hydroxytryptamine antagonist: monotherapy in essential hypertension.

Authors:  T Hedner; B Persson; G Berglund
Journal:  Br J Clin Pharmacol       Date:  1983-08       Impact factor: 4.335

7.  Prediction of metabolic drug interactions involving beta-adrenoceptor blocking drugs.

Authors:  B K Park
Journal:  Br J Clin Pharmacol       Date:  1984       Impact factor: 4.335

Review 8.  Ketanserin: a new hypotensive drug?

Authors:  A Amery; R Fagard; R Fiocchi; P Lijnen; J Staessen; L Vanhees
Journal:  J Cardiovasc Pharmacol       Date:  1985       Impact factor: 3.105

9.  The effect of a 5-HT antagonist, ketanserin, on blood pressure, the renin-angiotensin system and sympathoadrenal function in normal man.

Authors:  C Zoccali; J R Zabludowski; C G Isles; G D Murray; G C Inglis; J I Robertson; R Fraser; S G Ball
Journal:  Br J Clin Pharmacol       Date:  1983-09       Impact factor: 4.335

  9 in total
  7 in total

Review 1.  Clinical pharmacokinetics of ketanserin.

Authors:  B Persson; J Heykants; T Hedner
Journal:  Clin Pharmacokinet       Date:  1991-04       Impact factor: 6.447

Review 2.  Pharmacokinetic Variability of Drugs Used for Prophylactic Treatment of Migraine.

Authors:  Peer Tfelt-Hansen; Frederik Nybye Ågesen; Agniezka Pavbro; Jacob Tfelt-Hansen
Journal:  CNS Drugs       Date:  2017-05       Impact factor: 5.749

Review 3.  Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

4.  β-Adrenergic Contributions to Emotion and Physiology During an Acute Psychosocial Stressor.

Authors:  Jennifer K MacCormack; Emma L Armstrong-Carter; Monica M Gaudier-Diaz; Samantha Meltzer-Brody; Erica K Sloan; Kristen A Lindquist; Keely A Muscatell
Journal:  Psychosom Med       Date:  2021 Nov-Dec 01       Impact factor: 4.312

5.  Methoxycarbonyl-etomidate: a novel rapidly metabolized and ultra-short-acting etomidate analogue that does not produce prolonged adrenocortical suppression.

Authors:  Joseph F Cotten; S Shaukat Husain; Stuart A Forman; Keith W Miller; Elizabeth W Kelly; Hieu H Nguyen; Douglas E Raines
Journal:  Anesthesiology       Date:  2009-08       Impact factor: 7.892

6.  Effects of 5-hydroxytryptamine on human isolated placental chorionic arteries and veins.

Authors:  J Reviriego; J Marín
Journal:  Br J Pharmacol       Date:  1989-04       Impact factor: 8.739

7.  Development and Evaluation of a Physiologically Based Pharmacokinetic Drug-Disease Model of Propranolol for Suggesting Model Informed Dosing in Liver Cirrhosis Patients.

Authors:  Muhammad Nasir Kalam; Muhammad Fawad Rasool; Faleh Alqahtani; Imran Imran; Asim Ur Rehman; Naveed Ahmed
Journal:  Drug Des Devel Ther       Date:  2021-03-17       Impact factor: 4.162

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.